Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

The early use of antibiotics for ‘at risk’ children with influenza

Double-blind randomised placebo-controlled trial whose primary objective is to determine whether treatment with a 5-day course of co-amoxiclav early during an influenza/ILI episode in at risk children reduces the likelihood of re-consultation due to clinical deterioration.


‘At risk’ children are defined as children with underlying medical conditions or risk factors associated with an increased likelihood of developing influenza/ILI-related complications. Influenza/ILI is well recognised as a predisposing factor for secondary complications, including bacterial infections, which may result in children consulting a clinician more than once during the same illness episode due to clinical deterioration. Influenza and influenza-like illness (ILI) in children create a considerable burden on NHS resources each winter.

An effective, evidence-based policy on antibiotic use in at risk children during influenza season is needed to ensure that national antibiotic stockpiles are used in the most clinically appropriate and cost-effective way. This trial will determine whether early treatment with the antibiotic co-amoxiclav reduces the likelihood of re-consultation due to clinical deterioration in at risk children who present with influenza/ILI in primary care.


Study Design: Double-blind randomised placebo-controlled trial
Sponsor: University of Oxford
Chief Investigator: Dr Kay Wang, University of Oxford
Ethical approval: EudraCT Number: 2013-002822-21
Contact Details
Study website: